Goldberg; Stacie M.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Goldberg; Stacie M..The latest application filed is for "cancer immunotherapy by disrupting pd-1/pd-l1 signaling".

Company Profile

19.15.16

Goldberg; Stacie M. - Potomac MD
Goldberg; Stacie M. - Princeton NJ

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Cancer Immunotherapy By Disrupting Pd-1/pd-l1 Signaling App 20200308282 - COGSWELL; John P. ; et al.	2020-10-01
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling Grant 10,604,575 - Cogswell , et al.	2020-03-31
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling Grant 10,584,170 - Cogswell , et al.	2020-03-10
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling Grant 10,577,423 - Cogswell , et al.	2020-03-03
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling Grant 10,323,093 - Cogswell , et al.	2019-06-18
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling Grant 10,323,092 - Cogswell , et al.	2019-06-18
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling Grant 10,316,090 - Cogswell , et al.	2019-06-11
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling Grant 10,316,091 - Cogswell , et al.	2019-06-11
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling Grant 10,308,714 - Cogswell , et al.	2019-06-04
Cancer Immunotherapy By Disrupting Pd-1/pd-l1 Signaling App 20190153099 - COGSWELL; John P. ; et al.	2019-05-23
Cancer Immunotherapy By Disrupting Pd-1/pd-l1 Signaling App 20190135920 - Cogswell; John P. ; et al.	2019-05-09
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling Grant 10,266,594 - Cogswell , et al.	2019-04-23
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling Grant 10,266,595 - Cogswell , et al.	2019-04-23
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling Grant 10,266,596 - Cogswell , et al.	2019-04-23
Cancer Immunotherapy By Disrupting Pd-1/pd-l1 Signaling App 20190112376 - COGSWELL; John P. ; et al.	2019-04-18
Cancer Immunotherapy By Disrupting Pd-1/pd-l1 Signaling App 20190112377 - COGSWELL; John P. ; et al.	2019-04-18
Cancer Immunotherapy By Disrupting Pd-1/pd-l1 Signaling App 20190100589 - Cogswell; John P. ; et al.	2019-04-04
Cancer Immunotherapy By Disrupting Pd-1/pd-l1 Signaling App 20190100590 - Cogswell; John P. ; et al.	2019-04-04
Cancer Immunotherapy By Disrupting Pd-1/pd-l1 Signaling App 20190092863 - Cogswell; John P. ; et al.	2019-03-28
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling Grant 10,138,299 - Cogswell , et al. Nov	2018-11-27
Cancer Immunotherapy By Disrupting Pd-1/pd-l1 Signaling App 20180319887 - Cogswell; John P. ; et al.	2018-11-08
Cancer Immunotherapy By Disrupting Pd-1/pd-l1 Signaling App 20180312590 - COGSWELL; John P. ; et al.	2018-11-01
Cancer Immunotherapy By Disrupting Pd-1/pd-l1 Signaling App 20180282413 - COGSWELL; John P. ; et al.	2018-10-04
Cancer Immunotherapy By Disrupting Pd-1/pd-l1 Signaling App 20180282414 - COGSWELL; John P. ; et al.	2018-10-04
Cancer Immunotherapy By Disrupting Pd-1/pd-l1 Signaling App 20180273624 - COGSWELL; John P. ; et al.	2018-09-27
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling Grant 10,072,082 - Cogswell , et al. September 11, 2	2018-09-11
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling Grant 9,856,320 - Cogswell , et al. January 2, 2	2018-01-02
Cancer Immunotherapy By Disrupting Pd-1/pd-l1 Signaling App 20160090417 - COGSWELL; JOHN P. ; et al.	2016-03-31
Antibodies that bind PD-L1 and uses thereof Grant 9,212,224 - Cogswell , et al. December 15, 2	2015-12-15
Cancer Immunotherapy By Disrupting Pd-1/pd-l1 Signaling App 20150125463 - Cogswell; John P. ; et al.	2015-05-07
Cancer Immunotherapy By Disrupting Pd-1/pd-l1 Signaling App 20130309250 - Cogswell; John ; et al.	2013-11-21

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.